D. Boral Capital reissued their buy rating on shares of OS Therapies (NYSE:OSTX - Free Report) in a report published on Wednesday,Benzinga reports. They currently have a $20.00 target price on the stock.
Separately, Maxim Group initiated coverage on shares of OS Therapies in a report on Tuesday, November 26th. They issued a "buy" rating and a $8.00 price target for the company.
Read Our Latest Stock Report on OS Therapies
OS Therapies Stock Performance
Shares of OSTX stock traded up $0.20 during trading hours on Wednesday, reaching $4.36. The company had a trading volume of 19,030,647 shares, compared to its average volume of 2,159,065. The company's fifty day simple moving average is $3.26. OS Therapies has a twelve month low of $1.58 and a twelve month high of $7.00.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in OS Therapies stock. Virtu Financial LLC bought a new stake in OS Therapies Inc (NYSE:OSTX - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 10,045 shares of the company's stock, valued at approximately $28,000.
About OS Therapies
(
Get Free Report)
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.
See Also
Before you consider OS Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OS Therapies wasn't on the list.
While OS Therapies currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
